Eagle Bay Advisors LLC Athira Pharma, Inc. Transaction History

Eagle Bay Advisors LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 22, 2022	SELL	$2.93 - $3.96 $1,465 - $1,980	-500 Closed	0 $0
Q2 2022 Aug 19, 2022	BUY	$2.74 - $13.43 $1,370 - $6,715	500 New	500 $1.53 Million
Q1 2022 May 11, 2022	SELL	$8.96 - $13.51 $2,240 - $3,377	-250 Closed	0 $0
Q4 2021 Jan 21, 2022	SELL	$9.17 - $16.39 $1,375 - $2,458	-150 Reduced 37.5%	250 $3,000
Q3 2021 Nov 12, 2021	BUY	$9.15 - $11.09 $2,745 - $3,327	300 Added 300.0%	400 $4,000
Q2 2021 Jul 30, 2021	BUY	$10.24 - $20.87 $1,024 - $2,087	100 New	100 $2,000

16.9M

112K

68K

Ticker ATHA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,817,700
Market Cap $25M
Description
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical tri...

Get notified when there are updates to the investment portfolio of Eagle Bay Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Eagle Bay Advisors LLC with notifications on news.